# Dartsbio Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dartsbio-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Zhongshan, China
- Website: www.dartsbio.com
- Total disclosed funding: $30M
- Latest round: Series B (Jan 20, 2023)
- Investors on record: 7

## About

Established in 2017 and based in Zhongshan, China, Dartsbio Pharmaceuticals is an innovative antibody drug discovery and development company. The company's chief scientist officer and co-founder, Dr. Chunhe Wang, is a Ph.D. from the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and a post-doctoral fellow at Oregon Health Sciences University. The company is headquartered in Zhongshan and has a subsidiary in Shanghai. In June 2024, it closed a strategic investment. The company's business is the innovative development of antibody drugs, with a particular focus on oncology and pain management. The company's self-developed products include a range of antibody drugs and drug conjugates. Its products are mainly used in biomedical research and clinical applications. The company generates revenue by advancing its proprietary pipeline of antibody drugs through various stages of clinical development and by licensing its intellectual property to pharmaceutical and biotechnology companies. In August 2025, Dartsbio Pharmaceuticals closed a venture funding from new investor Shouzhengyongqi Fund.

## Funding rounds

- Series B, Jan 20, 2023, $15M — Yuecai Zhongyin Private Equity, Kaitai Capital, Next Fund, Tongdu Investment, Xiangshang Investment, Cuiheng Group
- Series A, Aug 31, 2021, $15M — Kaitai Capital, Share Capital, Xiangshang Investment

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A, Series B
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A
- Xiangshang Investment — Series A, Series B
- Yuecai Zhongyin Private Equity (https://capitalatlas.ai/funds/yuecai-zhongyin-private-equity) — Series B
- Next Fund (https://capitalatlas.ai/funds/next-fund) — Series B
- Tongdu Investment — Series B
- Cuiheng Group — Series B